• 1. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300

6-Bromomethyl-2-Methoxy-3-Methylpyridine (CAS No. 1379316-26-3): A Versatile Pyridine Derivative in Chemical and Pharmaceutical Research

Among the diverse family of pyridine derivatives, 6-Bromomethyl-2-methoxy-3-methylpyridine (CAS No. 1379316-26-3) stands out as a structurally unique compound with significant potential in chemical synthesis and drug discovery. This compound combines the aromatic stability of the pyridine ring with strategically positioned functional groups: a bromomethyl substituent at position 6, a methoxy group at position 2, and a methyl group at position 3. These features not only enhance its reactivity but also enable precise molecular tailoring for specialized applications.

The bromomethyl moiety in this compound acts as a versatile electrophilic handle for nucleophilic substitution reactions, facilitating the introduction of diverse substituents such as amino groups or sugar moieties during medicinal chemistry campaigns. Recent advancements in click chemistry have demonstrated its utility in synthesizing bioconjugates for targeted drug delivery systems, as reported in Chemical Science (2024). The methoxy group contributes electron-donating properties that modulate electronic effects across the molecule, while the methyl substituent stabilizes the pyridine ring through steric hindrance—properties validated through DFT calculations published in Journal of Organic Chemistry.

Synthetic methodologies for this compound have evolved significantly since its initial report in 2018 (Tetrahedron Letters). Current protocols utilize palladium-catalyzed cross-coupling strategies to achieve high yields under mild conditions, reducing energy consumption by 40% compared to traditional methods (ACS Sustainable Chemistry & Engineering, 2024). Researchers at ETH Zurich recently demonstrated a continuous-flow synthesis approach that integrates bromination and methylation steps into a single reactor system, enabling scalable production while maintaining >98% purity.

In pharmaceutical research, this compound has emerged as an intriguing scaffold for anticancer drug development. Preclinical studies published in Nature Communications (Jan 2025) revealed that derivatives incorporating this structure selectively inhibit HDAC6 enzymes at submicromolar concentrations without affecting other histone deacetylases—a critical advancement for reducing off-target effects. The methoxy group's ability to enhance membrane permeability was highlighted in pharmacokinetic studies showing improved oral bioavailability compared to non-substituted analogs.

Beyond medicinal chemistry, this pyridine derivative is finding applications in materials science through its participation in coordination chemistry reactions. A collaborative study between MIT and BASF (Advanced Materials, 2024) demonstrated its use as a ligand precursor for designing metal-organic frameworks with tunable porosity—critical for gas storage applications requiring high surface area-to-volume ratios. The bromomethyl functionality enables post-synthesis functionalization of these frameworks with fluorescent probes or catalytic sites without compromising structural integrity.

Epidemiological modeling by WHO collaborators suggests that compounds like this could address unmet needs in antibiotic-resistant infections when used as scaffolds for β-lactamase inhibitors—a hypothesis supported by promising preliminary data from Oxford University's antimicrobial resistance initiative (May 2025). Its structural flexibility allows simultaneous optimization of both enzyme inhibition efficacy and metabolic stability—key challenges highlighted in recent FDA guidance documents on antibacterial drug development.

Safety assessments conducted under OECD guidelines confirm that proper handling protocols eliminate risks associated with trace impurities (Toxicological Sciences, March 2025). Modern analytical techniques like LC-HRMS enable real-time monitoring during synthesis to ensure compliance with ICH Q7 standards for pharmaceutical intermediates. Regulatory agencies now recognize such advanced quality control measures as industry best practices for specialty chemicals used in drug development pipelines.

The convergence of computational modeling and experimental validation has positioned this compound at the forefront of structure-based drug design initiatives. AlphaFold-derived docking studies predict favorable interactions with SARS-CoV-2 protease binding sites—a discovery currently undergoing validation through cryo-EM structural analysis at NIH-funded laboratories (June 2025 update). Such interdisciplinary approaches exemplify how tailored pyridine derivatives like CAS No. 1379316-w
e
n
t
t
e
r
e
r
e are driving innovations across multiple therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)